statistiche ricercatore

statistiche per MASSANO, DAVIDE

Distribuzione geografica

Salva come PNG Salva come JPEG

Continente	#
NA - Nord America	460
EU - Europa	277
AS - Asia	127
AF - Africa	2
Continente sconosciuto - Info sul continente non disponibili	1
Totale	867

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	457
CN - Cina	76
DK - Danimarca	75
IT - Italia	71
FR - Francia	34
SE - Svezia	26
UA - Ucraina	24
VN - Vietnam	20
DE - Germania	14
FI - Finlandia	13
AT - Austria	9
IN - India	7
GB - Regno Unito	6
JP - Giappone	4
KR - Corea	3
TR - Turchia	3
CA - Canada	2
EG - Egitto	2
IR - Iran	2
JO - Giordania	2
PL - Polonia	2
SG - Singapore	2
TH - Thailandia	2
UZ - Uzbekistan	2
CH - Svizzera	1
EU - Europa	1
GR - Grecia	1
HK - Hong Kong	1
ID - Indonesia	1
IQ - Iraq	1
MX - Messico	1
RO - Romania	1
TW - Taiwan	1
Totale	867

Salva come PNG Salva come JPEG

Città	#
Ann Arbor	182
Beijing	58
Fairfield	41
Torino	35
Villeurbanne	26
Dearborn	23
Houston	20
Jacksonville	19
Dong Ket	18
Cambridge	14
Ashburn	13
Wilmington	13
Fremont	11
Seattle	11
Woodbridge	10
Vienna	9
Redwood City	8
Hefei	4
Pisa	4
Città Di Castello	2
Guangzhou	2
Nanchang	2
Singapore	2
Toronto	2
Warsaw	2
Wuhan	2
Acton	1
Baotou	1
Bari	1
Bethesda	1
Central District	1
Coventry	1
Fuzhou	1
Garza García	1
Jinan	1
Kunming	1
Los Angeles	1
Milan	1
Nanjing	1
Nanning	1
Ningbo	1
Phoenix	1
Piemonte	1
Rivalta Di Torino	1
Rome	1
San Diego	1
San Mateo	1
Sassari	1
Savona	1
Siena	1
Taipei	1
Tampa	1
Tehran	1
Tokyo	1
Uhingen	1
Verona	1
Vistrorio	1
Zhoushan	1
Totale	565

Salva come PNG Salva come JPEG

Nome	#
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients.	136
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment	134
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia	124
Role of pharmacogenetics on deferasirox AUC and efficacy	123
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children	71
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes	57
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients	45
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients	45
Deferasirox AUC efficacy cutoff and role of pharmacogenetics	44
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness	43
Clinical relevance of deferasirox trough levels in β-thalassemia patients	39
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients	35
Deferiprone	25
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients	23
Totale	944

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	944
article - articoli	0
book - libri	0
conference - conferenze	43
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	987

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2016/2017	26	0	0	0	0	0	0	0	0	0	0	24	2
2017/2018	172	4	14	25	2	14	6	3	21	56	21	4	2
2018/2019	67	3	0	8	3	4	3	4	6	2	10	16	8
2019/2020	219	7	1	2	16	20	48	22	14	8	25	26	30
2020/2021	183	17	12	9	9	17	15	9	5	17	6	29	38
2021/2022	246	20	20	20	26	16	36	23	18	11	10	46	0
Totale													944